Methods of Optimizing Dissolved Oxygen Levels in Cell Culture
Summary
USPTO published patent application US20260109930A1 for Genzyme Corporation on April 23, 2026, covering methods of selecting an optimal fixed orientation of a dissolved oxygen probe in a perfusion bioreactor and culturing mammalian cells with the probe positioned at the selected orientation. The application was originally filed on October 6, 2023 as Application No. 19118698. The invention names Ethan Disston Penner, Charles Budde, and Jeffrey Swana as inventors and relates to CPC classifications C12M and C12N in the biotech cell culture domain.
“Provided herein are methods of selecting an optimal fixed orientation of a dissolved oxygen (DO) probe in a perfusion bioreactor and culturing a mammalian cell in a perfusion bioreactor having the DO probe positioned at the selected fixed orientation.”
About this source
GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 258 changes logged to date.
What changed
USPTO published patent application US20260109930A1 for Genzyme Corporation, covering methods of selecting optimal fixed orientations of dissolved oxygen probes in perfusion bioreactors and culturing mammalian cells with the probe positioned at the selected orientation. The application was filed October 6, 2023 and published April 23, 2026, naming three inventors: Ethan Disston Penner, Charles Budde, and Jeffrey Swana. This publication does not grant any rights; it makes the application publicly available for examination and potential opposition. Competitors in cell culture bioprocessing may review the application to assess freedom-to-operate implications for their own perfusion bioreactor systems.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS OF OPTIMIZING DISSOLVED OXYGEN LEVELS IN CELL CULTURE
Application US20260109930A1 Kind: A1 Apr 23, 2026
Assignee
Genzyme Corporation
Inventors
Ethan Disston Penner, Charles Budde, Jeffrey Swana
Abstract
Provided herein are methods of selecting an optimal fixed orientation of a dissolved oxygen (DO) probe in a perfusion bioreactor and culturing a mammalian cell in a perfusion bioreactor having the DO probe positioned at the selected fixed orientation.
CPC Classifications
C12M 41/34 C12M 29/10 C12M 41/12 C12M 41/32 C12M 41/36 C12M 41/44 C12N 5/0602
Filing Date
2023-10-06
Application No.
19118698
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.